BioSpace News Archive

Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today shared the results of an exploratory analysis evaluating the effects of patient characteristics on baseline vaginal/vulvar symptoms during its Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1) study.

Sermonix Pharmaceuticals today shared the results of EQUALS 2 (ESR1 QUAlity of Life Survey 2), a survey on the vaginal and sexual health of patients with ER+/HER2- metastatic breast cancer.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or the “ Company ”), an innovative medical imaging technology company, today announced it will host an Investor Day at the Nasdaq in New York City on Tuesday, October 17, 2023.

The Bladder Cancer Advocacy Network announced its exclusive partnership with Ferring Pharmaceuticals as the National Presenting Sponsor for its 2024 Walks to End Bladder Cancer.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that Gerald W. Bruce has been appointed as President and CEO of Novvae™ Pharmaceuticals.

BioTech Medics, Inc. is pleased to announce that the Company has acquired significant organic calcium carbonate assets and intends to begin supplying industry with calcium and produce a number of products to generate revenue.

Gilead Sciences, Inc. announced that Kevin E. Lofton, Lead Independent Director, has been named one of the most influential leaders in corporate governance by the National Association of Corporate Directors as part of their 2023 NACD Directorship 100™, an annual list of leading corporate directors and governance advocates.

Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announced today that on September 26, 2023, the USPTO granted a patent for its lead clinical asset, NEO-201, which is currently being tested in Phase 2 human Clinical Trials in the US.

Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, at the 2023 European Academy of Dermatology and Venereology (EADV) Congress to be held October 11-14 in Berlin.

BostonGene announced today that it will participate in and present at the Festival of Genomics & Biodata, which is being held October 5 - 6, 2023 in Boston, MA at the Boston Convention & Expo Center.